126 related articles for article (PubMed ID: 36762414)
1. Deconvolution of BNP and NT-proBNP Immunoreactivities by Mass Spectrometry in Heart Failure and Sacubitril/Valsartan Treatment.
Nougué H; Michel T; Picard F; Lassus J; Sadoune M; Laribi S; Cohen-Solal A; Logeart D; Launay JM; Vodovar N
Clin Chem; 2023 Apr; 69(4):350-362. PubMed ID: 36762414
[TBL] [Abstract][Full Text] [Related]
2. Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan.
Dillon EM; Wei SD; Gupta DK; Nian H; Rodibaugh BS; Bachmann KN; Naftilan AJ; Stevenson LW; Brown NJ
J Card Fail; 2021 Nov; 27(11):1231-1239. PubMed ID: 34133968
[TBL] [Abstract][Full Text] [Related]
3. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
4. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
5. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
6. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Ibrahim NE; McCarthy CP; Shrestha S; Gaggin HK; Mukai R; Szymonifka J; Apple FS; Burnett JC; Iyer S; Januzzi JL
J Am Coll Cardiol; 2019 Mar; 73(11):1273-1284. PubMed ID: 30898202
[TBL] [Abstract][Full Text] [Related]
7. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
[TBL] [Abstract][Full Text] [Related]
8. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
10. Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides.
Roubille F; Delseny D; Cristol JP; Merle D; Salvetat N; Larue C; Davy JM; Leclercq F; Pasquie JL; Guerrier L; Fareh J; Dupuy AM
PLoS One; 2013; 8(9):e75174. PubMed ID: 24069392
[TBL] [Abstract][Full Text] [Related]
11. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Mann DL; Givertz MM; Vader JM; Starling RC; Shah P; McNulty SE; Anstrom KJ; Margulies KB; Kiernan MS; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; DeVore AD; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JAMA Cardiol; 2022 Jan; 7(1):17-25. PubMed ID: 34730769
[TBL] [Abstract][Full Text] [Related]
12. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
13. Evolution of B-type natriuretic peptide and N-terminal pro-brain natriuretic peptide during acute decompensated heart failure in a chronic heart failure patient with reduced ejection fraction treated with Sacubitril/Valsartan: a case report.
Tiepolo A; Nougué H; Damoisel C; Launay JM; Vodovar N; Mebazaa A
Eur Heart J Case Rep; 2019 Sep; 3(3):ytz108. PubMed ID: 31660484
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
15. Assays Specific for BNP1-32 and NT-proBNP Exhibit a Similar Performance to Two Widely Used Assays in the Diagnosis of Heart Failure.
Lewis LK; Raudsepp SD; Whitlow JC; Appleby S; Pemberton CJ; Yandle TG; Mark Richards A
Clin Chem; 2022 Oct; 68(10):1292-1301. PubMed ID: 35932191
[TBL] [Abstract][Full Text] [Related]
16. Cutting Edge of Brain Natriuretic Peptide (BNP) Research - The Diversity of BNP Immunoreactivity and Its Clinical Relevance.
Kuwahara K; Nakagawa Y; Nishikimi T
Circ J; 2018 Sep; 82(10):2455-2461. PubMed ID: 30135320
[TBL] [Abstract][Full Text] [Related]
17. Value of proBNP1-108 testing for the risk stratification of patients with systolic heart failure.
Gruson D; Lepoutre T; Ahn SA; Rousseau MF
Peptides; 2013 Dec; 50():125-8. PubMed ID: 24140405
[TBL] [Abstract][Full Text] [Related]
18. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
Piña IL; Camacho A; Ibrahim NE; Felker GM; Butler J; Maisel AS; Prescott MF; Williamson KM; Claggett BL; Desai AS; Solomon SD; Januzzi JL;
JACC Heart Fail; 2021 Jan; 9(1):42-51. PubMed ID: 33189630
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
Berg DD; Samsky MD; Velazquez EJ; Duffy CI; Gurmu Y; Braunwald E; Morrow DA; DeVore AD
Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
